Form 8-K - Current report:
SEC Accession No. 0001213900-24-098530
Filing Date
2024-11-14
Accepted
2024-11-14 16:56:16
Documents
14
Period of Report
2024-11-14
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0221362-8k_oruka.htm   iXBRL 8-K 27525
2 AUDITED FINANCIAL STATEMENT OF ORUKA THERAPEUTICS, INC. AS OF FEBRUARY 6, 2024 ea022136201ex99-1_oruka.htm EX-99.1 53712
  Complete submission text file 0001213900-24-098530.txt   269258

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE orka-20241114.xsd EX-101.SCH 3012
4 XBRL LABEL FILE orka-20241114_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE orka-20241114_pre.xml EX-101.PRE 22357
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0221362-8k_oruka_htm.xml XML 3678
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 241463883
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)